| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d78c2037dd3f1767290707556ac65151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_deb47a64dd7d0ec93cb98df1bbfd0608 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2006-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54086b25ed5d5f669384257cd2c78dfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91b11c29cecfbfb084af7c469cd6540f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5a9aa02db6705beef40a5014e9a2b0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b52db2cb398a547c37df86832db49383 |
| publicationDate |
2011-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0620888-A2 |
| titleOfInvention |
combination therapy using anti-egfr and anti-her2 antibodies |
| abstract |
COMBINATION THERAPY USING ANTI-EGFR AND ANTI-HER2 ANTIBODIES. The invention relates to the combined use of anti-EGFR antibodies and anti-HER2 antibodies for the treatment of cancer, especially suitable for cancer expressing high EGFR-like levels and low HER2 levels. The invention relates in particular to "trastuzumab (HERCEPTIN <32>) monoclonal antibody directed against HER2 receptors whose efficacy can be significantly increased in vivo when combined with" matuzumab "monoclonal antibody (hmAB 425, EMD 72000) directed against EGF receptors The combination treatment is suitable for cancer patients with the receptor profile, preferably pancreatic cancer. |
| priorityDate |
2006-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |